We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-21.35%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.43B
AUM Growth
-$314M
Cap. Flow
-$88.1M
Cap. Flow %
-3.63%
Top 10 Hldgs %
48.1%
Holding
447
New
130
Increased
120
Reduced
90
Closed
66

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$38.8M
2
BIIB icon
Biogen
BIIB
+$26M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$23.3M
4
VTRS icon
Viatris
VTRS
+$21M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$16.2M

Top Sells

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$28.9M
2
MRK icon
Merck
MRK
+$17.9M
3
XOM icon
ExxonMobil
XOM
+$14.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$13.4M
5
LPCN icon
Lipocine
LPCN
+$7.13M

Sector Composition

Rank Sector Weight
1 Healthcare 13.39%
2 Energy 1.08%
3 Technology 0.46%
4 Materials 0.45%
5 Consumer Discretionary 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTIC
251
CALL
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$839K 0.03%
575
– –
TNXP icon
252
Tonix Pharmaceuticals
TNXP
$152M
– –
0
– –
MNTA
253
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$821K 0.03%
+50,030
New +$1.02M
FOCL
254
PUT
EDAP TMS S.A.
FOCL
$234M
$819K 0.03%
1,466
-595
-29% -$2.3K
RDUS
255
DELISTED
Radius Health, Inc.
RDUS
$804K 0.03%
+11,600
New +$806K
TSRO
256
DELISTED
TESARO, Inc.
TSRO
$802K 0.03%
+20,000
New +$1.09M
TSRO
257
PUT
DELISTED
TESARO, Inc.
TSRO
$802K 0.03%
200
– –
ALDX icon
258
Aldeyra Therapeutics
ALDX
$97.1M
$787K 0.03%
134,997
-131,956
-49% -$1.03M
CYTK icon
259
PUT
Cytokinetics
CYTK
$10.6B
$787K 0.03%
1,176
+33
+3% +$225
ZSPH
260
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$780K 0.03%
11,875
-2,973
-20% -$179K
NURO
261
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$771K 0.03%
341
+29
+9% +$65.8K
BLCM
262
CALL
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$764K 0.03%
53
+37
+231% +$6.79K
CLRB icon
263
Cellectar Biosciences
CLRB
$19.8M
$751K 0.03%
13
-6
-32% -$546K
SSKN
264
DELISTED
Strata Skin Sciences
SSKN
$750K 0.03%
13,157
+4,070
+45% +$236K
SUNE
265
CALL
DELISTED
SUNEDISON, INC COM
SUNE
$718K 0.03%
+1,000
New +$17.9K
KPRX icon
266
Kiora Pharmaceuticals
KPRX
$11.4M
$695K 0.03%
+45
New +$1.03M
TTHI
267
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
$685K 0.03%
382,600
+79,763
+26% +$170K
FNCX
268
DELISTED
Function(x) Inc.
FNCX
$666K 0.03%
40,634
-58,212
-59% -$1.73M
DBVT
269
DBV Technologies
DBVT
$813M
$660K 0.03%
+1,854
New +$729K
ZSAN
270
DELISTED
Zosano Pharma Corporation
ZSAN
$647K 0.03%
233
-14
-6% -$78.6K
RNVA
271
DELISTED
Rennova Health, Inc.
RNVA
$635K 0.03%
205
+9
+5% +$24.5K
PTCT icon
272
PTC Therapeutics
PTCT
$6.18B
$624K 0.03%
+23,387
New +$1M
TTPH
273
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$606K 0.03%
+4,059
New +$2.98M
TPST icon
274
CALL
Tempest Therapeutics
TPST
$14.3M
– –
-1
Closed -$67.3K
CBAY
275
DELISTED
Cymabay Therapeutics
CBAY
$569K 0.02%
293,294
+193,294
+193% +$526K
9 10
11
12 13

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q3 2015 Portfolio in Review

As of Q3 2015, Sabby Management held 447 positions worth $2.43B, down 11% from $2.74B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Sabby Management withdrew a net $88.1M in Q3 2015, closing 66 positions and reducing 90 holdings. Its most notable exit was iShares 20+ Year Treasury Bond ETF, an estimated $28.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 8.3% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in iShares Russell 2000 ETF worth $35.7M.

  • Sabby Management's largest Q3 2015 buy was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.
  • Sabby Management added most to Mobileye N.V. in Q3 2015, an estimated $8.9M increase.
  • Sabby Management's biggest Q3 2015 reduction was Lipocine, cutting an estimated $7.13M.
  • Sabby Management fully exited iShares 20+ Year Treasury Bond ETF in Q3 2015, selling an estimated $28.9M.
  • Sabby Management's ten largest holdings make up 48% of its $2.43B portfolio in Q3 2015.
  • Sabby Management opened 130 new positions and closed 66 in Q3 2015.
  • Sabby Management's portfolio value fell 11% quarter-over-quarter to $2.43B.

Based on Sabby Management's 13F filing for Q3 2015, filed 16 Nov 2015.